Rebecca L. Murdaugh

Rebecca L. Murdaugh

Auto-generated profile, based on publicly available information

Rebecca L. Murdaugh

Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2021 in Science Advances
Verified
Journal Article
Open access
XSXiangguo Shi
Xiangguo Shi
YJYajian Jiang
Yajian Jiang
AKAyumi Kitano
Ayumi Kitano
THTianyuan Hu
Tianyuan Hu
RMRebecca L. Murdaugh
Rebecca L. Murdaugh
DNDaisuke Nakada
Daisuke Nakada
Nuclear NAD + homeostasis governed by NMNAT1 prevents apoptosis in AML stem cells by suppressing p53.

23 January 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
RRRosemary U. Richard
Rosemary U. Richard
CBCaitlin Bagnetto
Caitlin Bagnetto
RMRebecca L. Murdaugh
Rebecca L. Murdaugh
BEBrittany R. Eberl
Brittany R. Eberl
AJAlan L. Jiao
Alan L. Jiao
JAJamie Nicole Anastas
Jamie Nicole Anastas
Diffuse midline gliomas (DMG) are aggressive pediatric brain tumors characterized by chromatin and transcriptional dysregulation induced by H3K27M mutations. Strategies for overcoming epigenetic dysfunction to reduce DMG tumorigenesis remain limited. We identified multiple components of the SAGA and ATAC chromatin regulatory complexes as DMG genetic dependencies and found that genetic or pharmacological inhibition of the SAGA/ATAC-associated chromatin reader SGF29 reduces DMG proliferation. Small molecules targeting SAGA/ATAC-associated histone acetylation, ubiquitination, and methylation similarly suppressed DMG growth. Further chromatin profiling and RNAseq analyses reveal that SGF29 controls H3K9ac and H3K4me3 dynamics at both H3K27M-bound and H3K27M-independent target genes linked to proliferation, differentiation, and metabolism. Finally, we find that SAGA/ATAC inhibition may reduce DMG viability by repressing cholesterol metabolism gene expression and show that combinations of cholesterol- and SAGA/ATAC-targeting drugs synergistically reduce DMG growth. These findings reveal a functional link between SAGA/ATAC-dependent chromatin modulation and both transcriptional and metabolic dysregulation underlying DMG malignancy.

19 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AJAlan L. Jiao
Alan L. Jiao
RMRebecca L. Murdaugh
Rebecca L. Murdaugh
AKAdam F. Kebede
Adam F. Kebede
CMClaudia A. Mimoso
Claudia A. Mimoso
BZBarry M. Zee
Barry M. Zee
JAJamie Nicole Anastas
Jamie Nicole Anastas
Recurrent driver mutations in genes encoding histone H3 (H3.3K27M and H3.1K27M) are observed in ~80% of diffuse midline gliomas (DMG), which lead to aberrant gene regulation, yet the specific RNA polymerase II (Pol2) regulators that induce transcriptional dysregulation in DMG are not fully defined. We identified multiple regulators of Pol2 elongation as DMG genetic dependencies in a chromatin-focused CRISPR screen. Additional studies confirm that knockout (KO) of the Pol2 SIII complex gene elongin B (ELOB) inhibits DMG cell proliferation in tissue culture and tumor growth in xenograft models. Further genomic analyses reveal that ELOB binding sites are enriched in H3K27M oncohistones and that ELOB KO alters H3K27me3 and H3K27M incorporation at thousands of genomic regions, implicating ELOB in the maintenance of dysfunctional chromatin states in DMG. Correspondingly, PRO-seq and RNA-seq profiling reveal that ELOB loss disrupts Pol2 transcriptional activity and alters the expression of transcripts involved in metabolism, proliferation, and brain development. These findings suggest that Pol2 elongation factors like ELOB cooperate with H3K27M oncohistones to maintain the epigenetic and transcriptional landscape driving DMG malignancy.

1 June 2023 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
JAJamie Nicole Anastas
Jamie Nicole Anastas
AKAdam Kebede
Adam Kebede
AJAlan Jiao
Alan Jiao
CMClaudia Mimoso
Claudia Mimoso
RMRebecca Murdaugh
Rebecca Murdaugh
YSYang Shi
Yang Shi
Chromatin dysregulation is both a cause and consequence of aberrant RNA Polymerase II (Pol2) transcription in cancer. Some of the most striking examples of chromatin disruption in cancer include somatic mutations in genes encoding histone H3 (H3.3/H3.1K27M) observed in ~80% of diffuse midline glioma (DMG). H3K27M mutant histones act in a dominant manner to disrupt chromatin regulation and Pol2-dependent transcription in DMG. How H3K27M impinges on the Pol2 transcriptional machinery and whether aberrant Pol2 transcription can reciprocally induce chromatin dysregulation in DMG remain open questions. We conducted epigenome-focused CRISPR dropout screens and identified multiple regulators of Pol2 elongation, including Elongin B and C (ELOB/ELOC) as DMG genetic dependencies. Follow-up studies confirm that knockout (KO) of ELOB inhibits DMG proliferation in neurosphere culture and abrogates DMG tumorigenesis in orthotopic xenografts. Additional chromatin profiling studies reveal that ELOB binding sites are enriched in H3K27M mutant histones, suggesting that ELOB works together with H3K27M to promote malignant gene expression in DMG. Indeed, reciprocal knockout studies suggest that while ELOB chromatin binding patterns were not altered by H3K27M KO, ELOB KO significantly reduced H3K27M chromatin incorporation at thousands of genomic loci. Further RNAseq and PROseq analyses reveal that ELOB KO alters Pol2 transcription resulting in the up-regulation of genes associated with neuronal and muscle differentiation and the repression of glial stem cell genes. Together, these findings suggest that H3K27M chromatin binding patterns and aberrant gene regulation in DMG are, in part, dictated by ELOB and the Pol2 elongation machinery. Finally, analyses of patient datasets indicate that ELOB complex genes are overexpressed in high grade glioma and DMG and correlate with decreased patient survival. Collectively, these studies suggest that a functional interaction between ELOB and H3K27M mutant histones induces DMG-specific aberrations in chromatin and gene regulation to drive malignancy.

10 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
RMRebecca L. Murdaugh
Rebecca L. Murdaugh
BEBrittany R. Eberl
Brittany R. Eberl
RRRosemary U. Richard
Rosemary U. Richard
ECEna I. Campos-Hensley
Ena I. Campos-Hensley
ANAdanze N. Nnyagu
Adanze N. Nnyagu
JAJamie Nicole Anastas
Jamie Nicole Anastas
Aberrant neurotransmitter signaling and transcriptional dysregulation are hallmarks of gliomagenesis and represent potential therapeutic targets. Monoamine neurotransmitters such as dopamine and serotonin primarily activate GPCRs but can also function epigenetically as histone H3 modifications. Here, we uncover mechanisms of crosstalk between monoamine neurotransmitter signaling, H3 dopaminylation, and RNA polymerase II (Pol2) transcription in diffuse midline glioma (DMG). We find that co-treatment with Pol2-targeting CDK9 inhibitors (CDK9i) and FDA-approved neuropsychiatric drugs, including selective serotonin reuptake inhibitors (SSRIs), synergistically reduces DMG growth. Mechanistically, CDK9i+SSRI treatment alters H3 dopaminylation patterns and represses synaptic and neurodevelopmental gene transcription associated with CDK9i resistance. Further phospho-proteomic analyses show that CDK9i monotherapy activates pro-survival CaMKII signaling, which can be suppressed by co-treatment with neuromodulatory drugs. These studies establish roles for H3 dopaminylation and neurotransmitter signaling in DMG gene regulation and response to CDK9i, suggesting that monoamine neurotransmitter pathways may be exploited as a therapeutic strategy for DMG.